[go: up one dir, main page]

SI1887016T1 - Fragmenti človeškega horijevega gonadotropina (hcg) kot imunoregulator - Google Patents

Fragmenti človeškega horijevega gonadotropina (hcg) kot imunoregulator

Info

Publication number
SI1887016T1
SI1887016T1 SI200130895T SI200130895T SI1887016T1 SI 1887016 T1 SI1887016 T1 SI 1887016T1 SI 200130895 T SI200130895 T SI 200130895T SI 200130895 T SI200130895 T SI 200130895T SI 1887016 T1 SI1887016 T1 SI 1887016T1
Authority
SI
Slovenia
Prior art keywords
immunoregulator
hcg
fragments
immune
chorionic gonadotropin
Prior art date
Application number
SI200130895T
Other languages
English (en)
Inventor
Nisar Ahmed Khan
Robbert Benner
Original Assignee
Biotempt Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biotempt Bv filed Critical Biotempt Bv
Publication of SI1887016T1 publication Critical patent/SI1887016T1/sl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/59—Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g.hCG [human chorionic gonadotropin]; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/24—Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g. HCG; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/06—Antiabortive agents; Labour repressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Reproductive Health (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Cardiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Heart & Thoracic Surgery (AREA)
SI200130895T 2000-03-29 2001-03-29 Fragmenti človeškega horijevega gonadotropina (hcg) kot imunoregulator SI1887016T1 (sl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP00201139A EP1138692A1 (en) 2000-03-29 2000-03-29 Fragments of human chorionic gonadotropin (hcg) as immunoregulator
EP07108784A EP1887016B1 (en) 2000-03-29 2001-03-29 Fragments of human chorionic gonadotropin (hcg) as immunoregulator

Publications (1)

Publication Number Publication Date
SI1887016T1 true SI1887016T1 (sl) 2009-04-30

Family

ID=8171269

Family Applications (2)

Application Number Title Priority Date Filing Date
SI200130892T SI1272515T1 (sl) 2000-03-29 2001-03-29 Imunoregulator
SI200130895T SI1887016T1 (sl) 2000-03-29 2001-03-29 Fragmenti človeškega horijevega gonadotropina (hcg) kot imunoregulator

Family Applications Before (1)

Application Number Title Priority Date Filing Date
SI200130892T SI1272515T1 (sl) 2000-03-29 2001-03-29 Imunoregulator

Country Status (18)

Country Link
US (2) US7365155B2 (sl)
EP (3) EP1138692A1 (sl)
JP (1) JP5172064B2 (sl)
KR (1) KR100800876B1 (sl)
AT (2) ATE411340T1 (sl)
AU (1) AU781632B2 (sl)
CA (1) CA2407046C (sl)
CY (2) CY1108706T1 (sl)
DE (2) DE60136169D1 (sl)
DK (2) DK1272515T3 (sl)
ES (2) ES2315278T3 (sl)
HK (1) HK1052360B (sl)
IL (2) IL151945A0 (sl)
NZ (1) NZ521703A (sl)
PT (2) PT1887016E (sl)
SG (1) SG127739A1 (sl)
SI (2) SI1272515T1 (sl)
WO (1) WO2001072831A2 (sl)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1138692A1 (en) 2000-03-29 2001-10-04 Erasmus Universiteit Rotterdam Fragments of human chorionic gonadotropin (hcg) as immunoregulator
US20040202645A1 (en) * 2003-04-08 2004-10-14 Khan Nisar Ahmed Administration of gene-regulatory peptides
US8680059B2 (en) 1998-05-20 2014-03-25 Biotempt B.V. Oligopeptide acetate and formulations thereof
US20030220258A1 (en) 2001-12-21 2003-11-27 Robbert Benner Treatment of ischemic events
US7175679B2 (en) 2001-03-29 2007-02-13 Biotempt B.V. Oligopeptide treatment of NF-κB mediated inflammation
US20050227925A1 (en) * 2004-04-08 2005-10-13 Robbert Benner Compositions capable of reducing elevated blood urea concentration
US6844315B2 (en) 1998-05-20 2005-01-18 Erasmus Universiteit Rotterdam Immunoregulator
US6921751B1 (en) 1998-05-20 2005-07-26 Erasmus Universiteit Rotterdam Immunoregulator
US7576174B2 (en) 2000-03-29 2009-08-18 Biotempt B.V. Compositions capable of reducing elevated blood urea concentration
US20050037430A1 (en) * 2000-03-29 2005-02-17 Biotempt B.V. Methods and uses for protein breakdown products
EP1300418A1 (en) 2001-10-04 2003-04-09 Erasmus Universiteit Rotterdam Gene regulation by oligopeptides
USRE43279E1 (en) 2000-03-29 2012-03-27 Biotemp B.V. Compositions capable of reducing elevated blood urea concentration
US7358330B2 (en) 2001-03-29 2008-04-15 Biotempt B.V. Immunoregulatory compositions
US20030220259A1 (en) * 2001-12-21 2003-11-27 Robbert Benner Treatment of neurological disorders
US20030224995A1 (en) * 2001-12-21 2003-12-04 Khan Nisar Ahmed Treatment of burns
US20080318871A1 (en) * 2001-12-21 2008-12-25 Khan Nisar A Treatment of neurological disorders
US20080242837A1 (en) * 2001-12-21 2008-10-02 Khan Nisar A Peptide compositions
US20030220260A1 (en) * 2001-12-21 2003-11-27 Khan Nisar Ahmed Peptide compositions
US20030220261A1 (en) * 2001-12-21 2003-11-27 Khan Nisar Ahmed Treatment of iatrogenic disease
US7560433B2 (en) 2001-12-21 2009-07-14 Biotempt B.V. Treatment of multiple sclerosis (MS)
US7786084B2 (en) 2001-12-21 2010-08-31 Biotempt B.V. Treatment of burns
US20030220257A1 (en) * 2001-12-21 2003-11-27 Robbert Benner Treatment of trauma
US7501391B2 (en) 2001-12-21 2009-03-10 Biotempt B.V. Treatment of transplant survival
EP1466613A1 (en) * 2003-04-08 2004-10-13 Biotempt B.V. Compositions for mucosal and oral administration comprising hCG fragments
EP1466612A1 (en) * 2003-04-08 2004-10-13 Biotempt B.V. Treatment of inflammation and sepsis with hCG derived peptides
US7517529B2 (en) 2003-04-08 2009-04-14 Biotempt B.V. Treatment of type I diabetes
EP1466611A1 (en) * 2003-04-08 2004-10-13 Biotempt B.V. Use of HCG derived peptides in the treatment of iatrogenic diseases
WO2004093897A1 (en) * 2003-04-08 2004-11-04 Biotempt, B.V. Compositions for mucosal and oral administration comprising hcg fragments
US20090227505A1 (en) * 2004-01-07 2009-09-10 Biotempt B.V. Methods and uses for protein breakdown products
WO2006090874A1 (ja) * 2005-02-25 2006-08-31 Nihon University 哺乳動物ｔ細胞のサイトカインの分析方法と関連する一切の疾患の評価法と予防・治療の分析
CN101217971B (zh) * 2005-07-05 2011-11-09 比奥滕普特公司 肿瘤的治疗
DE102005054454A1 (de) * 2005-11-09 2007-06-28 Universität Duisburg-Essen Verwendung von Choriongonadotropin als Immunsuppressivum
EP1864692A1 (en) * 2006-06-07 2007-12-12 Biotempt B.V. Use of peptides for the control of radiation injury
WO2008100140A1 (en) * 2007-02-12 2008-08-21 Biotempt B.V. Treatment of trauma hemorrhage with short oligopeptides
US20080217002A1 (en) * 2007-03-07 2008-09-11 Floyd Randolph Simonds Sand control screen having a micro-perforated filtration layer
US20110136911A1 (en) * 2007-12-20 2011-06-09 The Feinstein Institute For Medical Research Treatment of sepsis and inhibition of mif by d-t4
EP2109054A1 (en) 2008-04-09 2009-10-14 Biotempt B.V. Methods for identifying biologically active peptides and predicting their function
EP2490021A1 (en) 2011-02-18 2012-08-22 Biotempt B.V. Modulators of PRR and GPCR signalling
CN104415162B (zh) * 2013-08-21 2018-05-15 常州市肿瘤医院 治疗放化疗后白细胞减少症的中药组合物及其制备方法

Family Cites Families (79)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4571336A (en) 1983-08-25 1986-02-18 Endorphin, Inc. Immune stimulation
US4977244A (en) 1985-06-27 1990-12-11 The United States Of America As Represented By The Department Of Health And Human Services Uromodulin and a process of purifying it
US4855285A (en) * 1985-12-04 1989-08-08 The Ohio State University Research Foundation Antigenic modification of polypeptides
SE8701921L (sv) 1986-05-12 1987-11-13 Wellcome Found Ny farmaceutisk anvendning
US5055447A (en) 1988-07-28 1991-10-08 Genentech, Inc. Method and compositions for the treatment and prevention of septic shock
US5308834A (en) 1989-02-14 1994-05-03 Incyte Pharmaceuticals, Inc. Treatment of endotoxin-associated shock and prevention thereof using a BPI protein
US5650489A (en) 1990-07-02 1997-07-22 The Arizona Board Of Regents Random bio-oligomer library, a method of synthesis thereof, and a method of use thereof
US6051596A (en) 1990-08-10 2000-04-18 Anormed, Inc. Immunosuppressive compositions
US5958413A (en) 1990-11-01 1999-09-28 Celltech Limited Use of antibodies to TNF or fragments derived thereof and xanthine derivatives for combination therapy and compositions therefor
AU2140592A (en) 1991-05-17 1992-12-30 Chiron Corporation Inhibitor of nf-kappa b transcriptional activator and uses thereof
DE4138621A1 (de) 1991-11-25 1993-06-17 Boehringer Ingelheim Int Verfahren zum screenen von substanzen mit modulierender wirkung auf einen rezeptorabhaengigen zellulaeren signaluebertragungsweg
ATE260971T1 (de) * 1992-04-01 2004-03-15 Univ Rockefeller Verfahren zur in vitro kultivierung dendritischer vorläuferzellen und deren verwendung zur immunogen herstellung
EP0572688B1 (en) 1992-05-30 1997-05-07 Predrag Dr.Sc. Sikiric Peptides with organo-protective activity, the process for preparing them and their use in therapy
US5436270A (en) 1993-04-07 1995-07-25 National Science Council Method for protecting against endotoxin-induced shock
US5380668A (en) 1993-07-06 1995-01-10 University Of Utah Research Foundation Compounds having the antigenicity of hCG
US5837478A (en) 1993-12-23 1998-11-17 Icos Corporation Method of identifying modulators of binding between and VCAM-1
US5677275A (en) 1994-08-05 1997-10-14 The United States Of America As Represented By The Department Of Health And Human Services Treatment of cancer with human chorionic gonadotropin
US5700781A (en) 1994-10-04 1997-12-23 Harris; Pamela Jo Method for treating Kaposi's sarcoma and HIV infections
US5851997A (en) 1994-10-04 1998-12-22 Harris; Pamela Jo Use of human chorionic gonadotropin as an immune-potentiating antiviral agent
SE520730C2 (sv) 1995-01-20 2003-08-19 Eskil Elmer Behandling av hjärnischemi och hjärnskador med ett neuroprotektivt läkemedel
US5981486A (en) 1995-04-13 1999-11-09 Chugai Seiyaku Kabushiki Kaisha Peptide suppressing IκBα phosphorylation
AU5161296A (en) 1995-04-21 1996-11-07 Allelix Biopharmaceuticals Inc. Anti-haemorrhagic peptides
US6361992B1 (en) 1996-05-08 2002-03-26 The United States Of America As Represented By The Department Of Health And Human Services Thyroid stimulating hormone superagonists
US6319504B1 (en) 1996-06-24 2001-11-20 University Of Maryland Biotechnology Institute Treatment and prevention of HIV infection by administration of derivatives of human chorionic gonadotropin
US5997871A (en) 1996-06-24 1999-12-07 University Of Maryland Biotechnology Insitute Treatment and prevention of cancer by administration of derivatives of human chorionic gonadotropin
US5968513A (en) * 1996-06-24 1999-10-19 University Of Maryland Biotechnology Institute Method of promoting hematopoiesis using derivatives of human chorionic gonadotropin
AU3587797A (en) * 1996-06-24 1998-01-14 University Of Maryland Biotechnology Institute Methods of treatment of wasting syndrome based on administration of derivatives of human chorionic gonadotropin
US6150500A (en) 1996-07-12 2000-11-21 Salerno; John C. Activators of endothelial nitric oxide synthase
GB9617021D0 (en) 1996-08-13 1996-09-25 Salpep Biotechnology Inc Novel peptides for treatment of inflammation and shock
US6346602B1 (en) 1997-02-07 2002-02-12 Thomas Jefferson University Peptide mimics of the cytokine receptor common γ chain and methods and compositions for making and using the same
JP2001511814A (ja) 1997-02-15 2001-08-14 プロスクリプト・インコーポレイテッド ＮＦ−κＢの阻害を介する梗塞の治療
US5801193A (en) 1997-04-15 1998-09-01 Immune Modulation, Inc. Compositions and methods for immunosuppressing
US6583109B1 (en) 1997-06-24 2003-06-24 Robert C. Gallo Therapeutic polypeptides from β-hCG and derivatives
DE19735587B4 (de) 1997-08-16 2012-03-22 Eberhard-Karls-Universität Tübingen Universitätsklinikum Peptid mit radioprotektiver Wirkung, dieses enthaltende kosmetische oder pharmazeutische Zusammensetzung, für dieses kodierende Nukleinsäure, Herstellungsverfahren für dieses Peptid und die Verwendung als radioprotektives Agens
HUP0001237A3 (en) 1997-10-20 2002-01-28 Lilly Co Eli Methods for treating vascular disorders
AU1552599A (en) 1997-12-12 1999-07-05 University Of Western Ontario, The Novel peptide, apoep1.b, compositions and uses thereof
US7175679B2 (en) 2001-03-29 2007-02-13 Biotempt B.V. Oligopeptide treatment of NF-κB mediated inflammation
AU755067B2 (en) * 1998-05-20 2002-12-05 Biotempt B.V. Immunoregulator
US6921751B1 (en) 1998-05-20 2005-07-26 Erasmus Universiteit Rotterdam Immunoregulator
US20030220258A1 (en) 2001-12-21 2003-11-27 Robbert Benner Treatment of ischemic events
US6844315B2 (en) 1998-05-20 2005-01-18 Erasmus Universiteit Rotterdam Immunoregulator
EP1138692A1 (en) 2000-03-29 2001-10-04 Erasmus Universiteit Rotterdam Fragments of human chorionic gonadotropin (hcg) as immunoregulator
RU2139085C1 (ru) 1998-06-23 1999-10-10 Санкт-Петербургская общественная организация "Институт биорегуляции и геронтологии" Средство, стимулирующее репаративные процессы, и способ его применения
CA2689373A1 (en) 1998-09-17 2000-03-30 Hopital Sainte-Justine G protein-coupled receptor antagonists
EP1131351A2 (en) 1998-11-20 2001-09-12 Mount Sinai Hospital Peptides that modulate the interaction of b class ephrins and pdz domains
US6507788B1 (en) 1999-02-25 2003-01-14 Société de Conseils de Recherches et D'Applications Scientifiques (S.C.R.A.S.) Rational selection of putative peptides from identified nucleotide, or peptide sequences, of unknown function
CA2366678A1 (en) 1999-03-09 2000-09-14 Fornix Biosciences N.V. Synthetic complementary peptides and ophthalmologic uses thereof
US20030148955A1 (en) 1999-04-19 2003-08-07 Pluenneke John D. Soluble tumor necrosis factor receptor treatment of medical disorders
RU2157233C1 (ru) 1999-05-11 2000-10-10 Санкт-Петербургская общественная организация "Институт биорегуляции и геронтологии" Тетрапептид, обладающий геропротекторной активностью, фармакологическое средство на его основе и способ его применения
US7994278B1 (en) 1999-08-06 2011-08-09 Nobel Biosciences Llc Biologically active polypeptides derived from a novel early stage pregnancy factor designated maternin (MA)
CN1377276A (zh) 1999-08-09 2002-10-30 特里帕普股份公司 含有三肽的药用组合物
US6864355B1 (en) 2000-05-02 2005-03-08 Yale University Inhibition of NF-κB activation by blockade of IKKβ-NEMO interactions at the NEMO binding domain
CN100497374C (zh) 1999-10-15 2009-06-10 莫维克借贷有限责任公司 与g蛋白激酶信号途径修饰剂形成的n-甲酰基肽受体复合物
RU2155063C1 (ru) 1999-10-20 2000-08-27 Санкт-Петербургская общественная организация "Институт биорегуляции и геронтологии" Тетрапептид, стимулирующий функциональную активность нейронов, фармакологическое средство на его основе и способ его применения
JP2003518477A (ja) 1999-11-18 2003-06-10 セレメディックス，インク． 反応性酸素種およびフリーラジカルの効力を中和するための組成物および方法
AU777721B2 (en) 2000-01-14 2004-10-28 Larson, Richard Peptide inhibitors of LFA-1/ICAM-1 interaction
AU2001232799A1 (en) 2000-02-11 2001-08-20 Eli Lilly And Company Protein c derivatives
AU2001245537A1 (en) 2000-03-10 2001-09-24 Monsanto Company Anti-hypertensive peptides
US7576174B2 (en) 2000-03-29 2009-08-18 Biotempt B.V. Compositions capable of reducing elevated blood urea concentration
EP1300418A1 (en) 2001-10-04 2003-04-09 Erasmus Universiteit Rotterdam Gene regulation by oligopeptides
US7358330B2 (en) 2001-03-29 2008-04-15 Biotempt B.V. Immunoregulatory compositions
US6783757B2 (en) 2000-06-01 2004-08-31 Kirkman Group, Inc. Composition and method for increasing exorphin catabolism to treat autism
US6586403B1 (en) 2000-07-20 2003-07-01 Salpep Biotechnology, Inc. Treating allergic reactions and inflammatory responses with tri-and dipeptides
US20020155106A1 (en) 2000-12-01 2002-10-24 Hammond David J. Method of identifying a ligand for a target molecule
WO2002085117A1 (en) 2001-04-24 2002-10-31 Eisai Co., Ltd. Methods and compositions for preventing and treating septic shock and endotoxemia
US20030220259A1 (en) 2001-12-21 2003-11-27 Robbert Benner Treatment of neurological disorders
US7786084B2 (en) 2001-12-21 2010-08-31 Biotempt B.V. Treatment of burns
US7501391B2 (en) 2001-12-21 2009-03-10 Biotempt B.V. Treatment of transplant survival
US20030224995A1 (en) 2001-12-21 2003-12-04 Khan Nisar Ahmed Treatment of burns
US20040013661A1 (en) 2001-12-21 2004-01-22 Gert Wensvoort Stratification
US20030220257A1 (en) 2001-12-21 2003-11-27 Robbert Benner Treatment of trauma
US7560433B2 (en) 2001-12-21 2009-07-14 Biotempt B.V. Treatment of multiple sclerosis (MS)
US20030220261A1 (en) 2001-12-21 2003-11-27 Khan Nisar Ahmed Treatment of iatrogenic disease
US20030220260A1 (en) 2001-12-21 2003-11-27 Khan Nisar Ahmed Peptide compositions
US7135286B2 (en) 2002-03-26 2006-11-14 Perlegen Sciences, Inc. Pharmaceutical and diagnostic business systems and methods
CN100525829C (zh) 2002-04-15 2009-08-12 美国国家红十字会 检测混合物中配体和靶标的方法
US7517529B2 (en) 2003-04-08 2009-04-14 Biotempt B.V. Treatment of type I diabetes
CN101217971B (zh) 2005-07-05 2011-11-09 比奥滕普特公司 肿瘤的治疗
EP1864692A1 (en) 2006-06-07 2007-12-12 Biotempt B.V. Use of peptides for the control of radiation injury

Also Published As

Publication number Publication date
EP1272515A2 (en) 2003-01-08
AU4891301A (en) 2001-10-08
CA2407046A1 (en) 2001-10-04
JP5172064B2 (ja) 2013-03-27
PT1272515E (pt) 2009-01-23
DK1887016T3 (da) 2009-03-02
WO2001072831A3 (en) 2002-04-25
CY1108706T1 (el) 2014-04-09
ES2317620T3 (es) 2009-04-16
US7365155B2 (en) 2008-04-29
KR20030060768A (ko) 2003-07-16
IL151945A0 (en) 2003-04-10
DE60136577D1 (de) 2008-12-24
EP1138692A1 (en) 2001-10-04
CA2407046C (en) 2011-02-15
HK1052360B (en) 2009-05-08
WO2001072831A2 (en) 2001-10-04
EP1272515B1 (en) 2008-10-15
EP1887016A1 (en) 2008-02-13
DE60136169D1 (de) 2008-11-27
ATE414104T1 (de) 2008-11-15
HK1052360A1 (en) 2003-09-11
US20030166556A1 (en) 2003-09-04
USRE43140E1 (en) 2012-01-24
JP2004503468A (ja) 2004-02-05
DK1272515T3 (da) 2009-02-09
CY1110259T1 (el) 2015-01-14
ES2315278T3 (es) 2009-04-01
KR100800876B1 (ko) 2008-02-04
IL151945A (en) 2010-04-29
SI1272515T1 (sl) 2009-04-30
ATE411340T1 (de) 2008-10-15
NZ521703A (en) 2005-06-24
PT1887016E (pt) 2009-02-20
AU781632B2 (en) 2005-06-02
EP1887016B1 (en) 2008-11-12
SG127739A1 (en) 2006-12-29

Similar Documents

Publication Publication Date Title
SI1887016T1 (sl) Fragmenti človeškega horijevega gonadotropina (hcg) kot imunoregulator
WO2003030934A3 (en) Cpg formulations and related methods
MY136095A (en) Use of human anti-ctla-4 antibodies for treatment of cancer
MY155218A (en) Small molecules useful in the treatment of inflammatory disease
DE69911401D1 (en) Immunoregulator
DE59807213D1 (de) 11beta-halogen-7alpha-substituierte-estratriene, verfahren zur herstellung pharmazeutischer präparate, die diese 11beta-halogen-7alpha-substituierte-estratriene enthalten, sowie deren verwendung zur herstellung von arzneimitteln
WO1998033509A3 (en) Useful properties of human lactoferrin and variants thereof
BR9509498A (pt) Agente aglutinante uso do mesmo composição farmacêutica e processo para tratamento de uma doença inflamatória autoimune ou uma doença alérgica
WO2002085311A3 (en) Hcg formulation
DE69924304D1 (de) N-palmitoylethanolamid-enthaltende pharmazeutische zusammensetzungen und deren verwendung in der veterinärmedizin
DE69821793D1 (de) Neuronale verwendungen des bmp-11
CA2408541A1 (en) Treating eczema and/or psoriasis
MY141459A (en) Recombinant anti-idiotypic antibodies
BR0111852A (pt) Nova interferona para o tratamento de esclerose múltipla
GB0312566D0 (en) Veterinary composition for the topical treatment of traumatized or inflamed skin
DE50207168D1 (de) Kombinationspräparat zur Therapie von immunologischen Erkrankungen
WO2001018041A3 (en) Flint proteins and formulations thereof
WO2003002066A3 (en) Glycosylated kinamycins and methods of making and using them
UA38284A (uk) Спосіб корекції дії барбітуратів
WO2001075036A3 (fr) Nouveau polypeptide, immunophiline humaine 14, et polynucleotide codant pour ce polypeptide
TJ387B (en) The present invention relates to medicine and can be used for treatment of inflammatory process of aleather.
WO2001075001A3 (en) A novel polypeptide, cyclic adenosine 9-dependant human protein kinase and the polynucleotide encoding the polypeptide
UA43543A (uk) Спосіб профілактики фетоплацентарної недостатності у вагітних з хламідійною інфекцією
WO2001094540A3 (en) A novel polypeptide, a human glucosyl hydrolase 23 and the polynucleotide encoding the polypeptide
WO2001083675A3 (en) A novel polypeptide, a atp-dependent human hydrolase serine 10.2 and the polynucleotide encoding the polypeptide